Do CCR5 antagonists improve the overall survival of patients with AIDS-related progressive multifocal leucoencephalopathy?

Introduction

Progressive multifocal leucoencephalopathy (PML), a devastating demyelinating disease caused by John Cunningham virus (JCV) reactivation, affects patients with severe immune deficiencies.1 Despite having tested numerous molecules over the last 25 years, their benefits have often been overstated based on isolated case reports or small series.1 Because those therapies offered patients with PML some, although limited, hope, the desire to try an inaccurately tested but potentially lifesaving treatment surpasses rigorous clinical trial evaluation before widespread use. Notably, cidofovir's alleged promise, based on case reports, largely evaporated when prospective cohort studies demonstrated that it had no influence on AIDS-related PML (AR-PML) overall survival (OS) or residual disability.2 That story might be repeating itself with maraviroc (MVC) use, also based on only a few favourable case reports.3

Restoring JCV-specific immune responses is the most effective way to improve survival of patients with PML.1 Immune...

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2Axhkma